ClearAlpha Technologies LP Buys New Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

ClearAlpha Technologies LP purchased a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the third quarter, HoldingsChannel reports. The fund purchased 6,895 shares of the specialty pharmaceutical company’s stock, valued at approximately $266,000.

Several other hedge funds also recently made changes to their positions in COLL. Pacer Advisors Inc. boosted its holdings in Collegium Pharmaceutical by 31.8% during the second quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock worth $109,749,000 after purchasing an additional 821,541 shares during the last quarter. Rubric Capital Management LP boosted its stake in shares of Collegium Pharmaceutical by 27.2% during the 2nd quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock worth $75,139,000 after buying an additional 499,473 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Collegium Pharmaceutical by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock valued at $90,479,000 after acquiring an additional 17,942 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of Collegium Pharmaceutical by 3.9% in the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock valued at $67,459,000 after acquiring an additional 64,958 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Collegium Pharmaceutical by 8.0% in the second quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock valued at $49,314,000 after acquiring an additional 113,300 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research analysts recently commented on COLL shares. Piper Sandler reissued a “neutral” rating and set a $37.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd. Truist Financial boosted their target price on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Finally, HC Wainwright boosted their price objective on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, September 5th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.60.

Insider Activity

In other news, EVP Thomas B. Smith sold 9,593 shares of the business’s stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $36.62, for a total transaction of $351,295.66. Following the completion of the sale, the executive vice president now owns 53,816 shares in the company, valued at $1,970,741.92. The trade was a 15.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the company’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the transaction, the executive vice president now directly owns 120,161 shares in the company, valued at $4,602,166.30. The trade was a 13.81 % decrease in their position. The disclosure for this sale can be found here. Insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Stock Up 2.7 %

COLL opened at $31.33 on Tuesday. The stock’s fifty day simple moving average is $34.81 and its 200 day simple moving average is $34.61. Collegium Pharmaceutical, Inc. has a 1-year low of $25.21 and a 1-year high of $42.29. The stock has a market cap of $1.01 billion, a PE ratio of 13.50 and a beta of 0.95. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.